Details of the Drug

General Information of Drug (ID: DM7J2TA)

Drug Name
Methazolamide
Synonyms Methazolamide (oral, sustained release)
Indication
Disease Entry ICD 11 Status REF
Glaucoma/ocular hypertension 9C61 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 236.3
Logarithm of the Partition Coefficient (xlogp) 0.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Elimination
61% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 14 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 21.162 micromolar/kg/day [4]
Vd
The volume of distribution (Vd) of drug is 17-23 L []
Water Solubility
The ability of drug to dissolve in water is measured as 0.704 mg/mL [2]
Chemical Identifiers
Formula
C5H8N4O3S2
IUPAC Name
N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide
Canonical SMILES
CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C
InChI
InChI=1S/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)
InChIKey
FLOSMHQXBMRNHR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4100
ChEBI ID
CHEBI:6822
CAS Number
554-57-4
DrugBank ID
DB00703
TTD ID
D0C2II
VARIDT ID
DR00599
ACDINA ID
D00408
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carbonic anhydrase I (CA-I) TTHQPL7 CAH1_HUMAN Modulator [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Gene/Protein Processing [6]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Gene/Protein Processing [7]
Galanin peptides (GAL) OTB3VPTO GALA_HUMAN Gene/Protein Processing [7]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Gene/Protein Processing [7]
Neuromodulin (GAP43) OT2OTGGV NEUM_HUMAN Gene/Protein Processing [7]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Glaucoma/ocular hypertension
ICD Disease Classification 9C61
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carbonic anhydrase I (CA-I) DTT CA1 5.23E-14 -0.11 -0.41
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methazolamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Dronedarone DMA8FS5 Major Increased risk of ventricular arrhythmias by the combination of Methazolamide and Dronedarone. Angina pectoris [BA40] [8]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Methazolamide and Levomilnacipran. Chronic pain [MG30] [9]
Sertraline DM0FB1J Moderate Increased risk of hyponatremia by the combination of Methazolamide and Sertraline. Depression [6A70-6A7Z] [9]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Methazolamide and Vilazodone. Depression [6A70-6A7Z] [9]
Paroxetine DM5PVQE Moderate Increased risk of hyponatremia by the combination of Methazolamide and Paroxetine. Depression [6A70-6A7Z] [9]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Methazolamide and Vortioxetine. Depression [6A70-6A7Z] [9]
Milnacipran DMBFE74 Moderate Increased risk of hyponatremia by the combination of Methazolamide and Milnacipran. Depression [6A70-6A7Z] [9]
Escitalopram DMFK9HG Moderate Increased risk of hyponatremia by the combination of Methazolamide and Escitalopram. Depression [6A70-6A7Z] [9]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Methazolamide and Desvenlafaxine. Depression [6A70-6A7Z] [9]
Primidone DM0WX6I Moderate Altered absorption of Methazolamide caused by Primidone. Epilepsy/seizure [8A61-8A6Z] [10]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Methazolamide and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [11]
Digitoxin DMWVIGP Moderate Increased risk of hypomagnesemia by the combination of Methazolamide and Digitoxin. Heart failure [BD10-BD1Z] [12]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Methazolamide and Captopril. Hypertension [BA00-BA04] [13]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Methazolamide and Perindopril. Hypertension [BA00-BA04] [13]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Methazolamide and Quinapril. Hypertension [BA00-BA04] [13]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Methazolamide and Lisinopril. Hypertension [BA00-BA04] [13]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Methazolamide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [14]
Sibutramine DMFJTDI Moderate Increased risk of hyponatremia by the combination of Methazolamide and Sibutramine. Obesity [5B80-5B81] [9]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Methazolamide and Levomethadyl Acetate. Opioid use disorder [6C43] [15]
Aspirin DM672AH Major Increased plasma concentration of Methazolamide and Aspirin due to competitive binding of plasma proteins. Pain [MG30-MG3Z] [16]
Choline salicylate DM8P137 Major Increased plasma concentration of Methazolamide and Choline salicylate due to competitive binding of plasma proteins. Postoperative inflammation [1A00-CA43] [17]
Salsalate DM13P4C Major Increased plasma concentration of Methazolamide and Salsalate due to competitive binding of plasma proteins. Rheumatoid arthritis [FA20] [17]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Methazolamide and Pimozide. Schizophrenia [6A20] [18]
Salicyclic acid DM2F8XZ Major Increased risk of metabolic acidosis by the combination of Methazolamide and Salicyclic acid. Seborrhoeic dermatitis [EA81] [16]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Methazolamide and Amiodarone. Ventricular tachyarrhythmia [BC71] [19]
⏷ Show the Full List of 25 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Brushite E00392 104805 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Glyceryl dibehenate E00537 22477175 Binding agent; Coating agent; Flavoring agent; Modified-release agent; Viscosity-controlling agent; lubricant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Methazolamide 25 mg tablet 25 mg Oral Tablet Oral
Methazolamide 50 mg tablet 50 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6828).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
6 Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J Biomol Screen. 2006 Oct;11(7):782-91.
7 Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics. 2002 Oct 29;11(2):45-52. doi: 10.1152/physiolgenomics.00064.2002.
8 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
9 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
10 Syversen GB, Morgan JP, Weintraub M, Myers GJ "Acetazolamide-induced interference with primidone absorption." Arch Neurol 34 (1977): 80-4. [PMID: 836189]
11 Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
12 Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
13 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
14 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
15 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
16 Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM "Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function." Br Med J (Clin Res Ed) 289 (1984): 347-8. [PMID: 6432091]
17 Anderson CJ, Kaufman PL, Sturm RJ "Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin." Am J Ophthalmol 86 (1978): 516-9. [PMID: 707596]
18 Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
19 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]